Skip to main content
European Commission logo
español español
CORDIS - Resultados de investigaciones de la UE
CORDIS

Dynamics of p53 mutant reactivation and the anti-carcinogenic action of engineered resveratrol analogues

Descripción del proyecto

Aplicación del resveratrol creado por bioingeniería en nuevos conceptos terapéuticos contra el cáncer

El resveratrol es un polifenol natural de origen vegetal que actúa contra los agentes patógenos, incluidas las bacterias y los hongos. El objetivo del proyecto p53-REACT, financiado por las Acciones Marie Skłodowska-Curie, es diseñar un hospedador bacteriano que produzca variantes del metabolito del resveratrol y estudiar su interacción con la proteína supresora de tumores p53. El propósito es dilucidar el modo de acción de las moléculas de resveratrol sobre los mutantes de p53, con vistas a nuevos conceptos para el tratamiento antineoplásico. El proyecto representa un amplio estudio de los derivados del resveratrol que actúan como inhibidores de la agregación de p53 y conlleva el uso de recursos informáticos de vanguardia y bioingeniería metabólica y estructural.

Objetivo

The project proposal aims to engineer a bacterial host to produce variants of secondary metabolite resveratrol and address the interrelationship between dynamics, structure and function of a system of high medical interest, the tumor suppressor protein p53. The study considers to elucidate the mode of action of these molecules against the p53 mutants and work on new concepts for cancer therapy. Inside the cell, the folding of a protein is a fast and robust process. Sometimes, however, sudden changes in the balance between different existing forces result in incorrect folding of the peptide chain, which ends up generating amyloid aggregates within the cell that lead to the gain of toxic function, since these aggregates can conduct to death of the cell in question. Most amyloidogenic pathologies are neurodegenerative, however the aggregation also plays an important role in cancer. The project provides a broad framework for the study of the resveratrol derivatives acting as p53 aggregation inhibitors by using cutting-edge tools of computational resources, metabolic engineering and structural biology. But could, in principal, be applied to exploit the chemical diversity of other biocompounds similarly intending to act as less cytotoxic agents in a more effective antineoplastic therapy, which represents one of the major existing scientific gaps. It is a proposal on a very important topic that will be studied from a unique perspective.

Coordinador

TECHNISCHE UNIVERSITAET MUENCHEN
Aportación neta de la UEn
€ 189 687,36
Dirección
Arcisstrasse 21
80333 Muenchen
Alemania

Ver en el mapa

Región
Bayern Oberbayern München, Kreisfreie Stadt
Tipo de actividad
Higher or Secondary Education Establishments
Enlaces
Coste total
Sin datos

Socios (1)